AbbVie (ABBV) Advances Cancer Treatments With Epcoritamab And Mirvetuximab Approvals
Health Canada’s recent approval of ELAHERE® for a challenging form of cancer marks a step forward for AbbVie in oncology, enhancing its presence in a high-need therapeutic area. Alongside this, the updated results presented from its EPCORE® NHL-6 trial further underscore the company’s commitment to advancing treatments in oncology. Yet, despite these developments, AbbVie’s stock…